HC Wainwright Reiterates “Buy” Rating for Emergent Biosolutions (NYSE:EBS)

HC Wainwright reaffirmed their buy rating on shares of Emergent Biosolutions (NYSE:EBS) in a research report released on Wednesday,Benzinga reports. HC Wainwright currently has a $15.00 price target on the biopharmaceutical company’s stock.

Separately, Wall Street Zen lowered Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Three analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $14.33.

Emergent Biosolutions Price Performance

NYSE:EBS opened at $7.57 on Wednesday. The company has a 50-day moving average of $7.58 and a 200-day moving average of $6.43. The company has a market capitalization of $403.60 million, a price-to-earnings ratio of 3.09 and a beta of 2.04. Emergent Biosolutions has a 52 week low of $4.02 and a 52 week high of $12.73. The company has a debt-to-equity ratio of 1.25, a quick ratio of 3.00 and a current ratio of 5.66.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.16 EPS for the quarter, beating the consensus estimate of ($0.26) by $0.42. The business had revenue of $140.90 million for the quarter, compared to analyst estimates of $148.55 million. Emergent Biosolutions had a return on equity of 24.63% and a net margin of 16.38%. As a group, equities research analysts anticipate that Emergent Biosolutions will post -0.63 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Kathryn C. Zoon sold 7,086 shares of Emergent Biosolutions stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $8.87, for a total transaction of $62,852.82. Following the completion of the transaction, the director directly owned 71,799 shares of the company’s stock, valued at $636,857.13. This trade represents a 8.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Donald W. Degolyer sold 7,844 shares of Emergent Biosolutions stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $8.65, for a total transaction of $67,850.60. Following the transaction, the director directly owned 137,659 shares of the company’s stock, valued at $1,190,750.35. This represents a 5.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Emergent Biosolutions

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Prescott Group Capital Management L.L.C. increased its position in Emergent Biosolutions by 198.9% in the 1st quarter. Prescott Group Capital Management L.L.C. now owns 627,671 shares of the biopharmaceutical company’s stock valued at $3,050,000 after acquiring an additional 417,671 shares in the last quarter. Bank of America Corp DE increased its position in Emergent Biosolutions by 4.4% in the 4th quarter. Bank of America Corp DE now owns 332,099 shares of the biopharmaceutical company’s stock valued at $3,175,000 after acquiring an additional 14,054 shares in the last quarter. New York State Common Retirement Fund raised its position in shares of Emergent Biosolutions by 22.4% during the first quarter. New York State Common Retirement Fund now owns 375,034 shares of the biopharmaceutical company’s stock worth $1,823,000 after acquiring an additional 68,748 shares during the last quarter. Harbor Capital Advisors Inc. bought a new stake in shares of Emergent Biosolutions during the first quarter worth $179,000. Finally, Cetera Investment Advisers raised its position in shares of Emergent Biosolutions by 28.5% during the first quarter. Cetera Investment Advisers now owns 356,281 shares of the biopharmaceutical company’s stock worth $1,732,000 after acquiring an additional 79,034 shares during the last quarter. Institutional investors and hedge funds own 78.40% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.